I'm trying to do something constructive here rather than just making a comment, in that I'm trying to put together an alternate motion.
I don't know if anyone else has seen this news. I texted my colleagues. News has just come out that Johnson & Johnson has been approved. I think this materially alters the need for the initial proposal, which I totally agree with. It was a good proposal and does address a very important question. Certainly, the numbers regarding AstraZeneca are all over the place, because there are a whole bunch of studies looking at whole bunch of end-points.
For me, the most crucial and I think the most conclusive study has come out of Scotland, where they've vaccinated over a million people. Over 400,000 got AstraZeneca. My understanding is that most of those people were over 80. After having received the AstraZeneca vaccination, they showed—I think after one month—a 94% reduction in hospitalization, which was actually better than Pfizer, which was somewhere in the eighties.
I think the fact is that AstraZeneca will be approved for an older population, but now Johnson & Johnson is out there as well. For the sake of Canadians, we're going to want some clarity, and hopefully at the national level, because as Michelle has said, and I think quite rightly, what all the provinces do could be different. Why not find out from NACI and from Health Canada what the recommendations are? As I say, now that Johnson & Johnson is out there, is that going to be a separate meeting?
I know that I'm speaking to Luc's amendment. I'm agnostic about the amendment, but I think there's a bigger issue on what exactly we're going to talk about. I was trying to come up with some kind of alternate proposal, which would be to put two hours aside sometime next week to discuss the newly authorized vaccines and the plan as to which populations would get which of those vaccines and based on what evidence.
Maybe I'm jumping the gun on that, but I thought I should point out the Johnson & Johnson approval. With Johnson & Johnson, too, that brings up other issues, because it too isn't as efficacious in preventing disease; however, the studies that came out show that it was 100% effective, at least in the limited population they had, at preventing hospitalization and death.
There is a big question: Who is going to get which of these vaccines? I absolutely agree with what everyone has said so far: I think that needs to be clarified.
Thank you.